ICCM IceCure Medical Ltd.

NASDAQ
$1.00

IceCure Medical Ltd. (ICCM) is expected to report earnings on February 17, 2027, before the market open. The consensus earnings estimate is a loss of $0.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on November 18, 2026.

IceCure Medical Beat Consensus Estimates
Wednesday, November 18, 2026 · 8:25 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 17
Wednesday · 8:30 AM ET
Earnings Whisper
-
vs ($0.84)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.03

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About IceCure Medical Ltd.

IceCure Medical develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.

Sector

Healthcare

Industry

Medical Instruments/Supply

Charts powered in part by Lightweight Charts™ by TradingView.